TY - JOUR
T1 - Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma
T2 - A report from the childhood cancer survivor study
AU - Jones, Lee W.
AU - Liu, Qi
AU - Armstrong, Gregory T.
AU - Ness, Kirsten K.
AU - Yasui, Yutaka
AU - Devine, Katie
AU - Tonorezos, Emily
AU - Soares-Miranda, Luisa
AU - Sklar, Charles A.
AU - Douglas, Pamela S.
AU - Robison, Leslie L.
AU - Oeffinger, Kevin C.
N1 - Publisher Copyright:
© 2014 by American Society of Clinical Oncology.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2014/11/10
Y1 - 2014/11/10
N2 - Purpose: Survivors of Hodgkin lymphoma (HL) are at increased risk of treatment-related cardiovascular (CV) events; whether exercise modifies this risk is unknown.Methods: Survivors of HL (n = 1, 187; median age, 31. 2 years) completed a questionnaire evaluating vigorous-intensity exercise behavior. CV events were collected in follow-up questionnaires and graded according to Common Terminology Criteria for Adverse Events (version 4. 03). The primary end point was incidence of any major (grade 3 to 5) CV event. Poisson regression analyses were used to estimate the association between exercise exposure (metabolic equivalent [MET] hours/week-1) and risk of major CV events after adjustment for clinica covariates and cancer treatment.Results: Median follow-up was 11. 9 years (range, 1. 7 to 14. 3 years). Cumulative incidence of any CV event was 12. 2% at 10 years for survivors reporting 0 MET hours/week-1 compared with 5. 2% for those reporting ≥ 9 MET hours/week-1. In multivariable analyses, the incidence of any CV event decreased across increasing MET categories (Ptrend =. 002). Compared with survivors reporting 0 MET hours/week-1, the adjusted rate ratio for any CV event was 0. 87 (95% CI, 0. 56 to 1. 34) for 3 to 6 MET hours/week-1, 0. 45 (95% CI, 0. 26 to 0. 80) for 9 to 12 MET hours/week-1, and 0. 47 (95% CI, 0. 23 to 0. 95) for 15 to 21 MET hours/week-1. Adherence to national vigorous intensity exercise guidelines (ie, ≥ 9 MET hours/week-1) was associated with a 51% reduction in the risk of any CV event in comparison with not meeting the guidelines (P =. 002).Conclusion: Vigorous exercise was associated with a lower risk of CV events in a dose-dependent manner ndependent of CV risk profile and treatment in survivors of HL.
AB - Purpose: Survivors of Hodgkin lymphoma (HL) are at increased risk of treatment-related cardiovascular (CV) events; whether exercise modifies this risk is unknown.Methods: Survivors of HL (n = 1, 187; median age, 31. 2 years) completed a questionnaire evaluating vigorous-intensity exercise behavior. CV events were collected in follow-up questionnaires and graded according to Common Terminology Criteria for Adverse Events (version 4. 03). The primary end point was incidence of any major (grade 3 to 5) CV event. Poisson regression analyses were used to estimate the association between exercise exposure (metabolic equivalent [MET] hours/week-1) and risk of major CV events after adjustment for clinica covariates and cancer treatment.Results: Median follow-up was 11. 9 years (range, 1. 7 to 14. 3 years). Cumulative incidence of any CV event was 12. 2% at 10 years for survivors reporting 0 MET hours/week-1 compared with 5. 2% for those reporting ≥ 9 MET hours/week-1. In multivariable analyses, the incidence of any CV event decreased across increasing MET categories (Ptrend =. 002). Compared with survivors reporting 0 MET hours/week-1, the adjusted rate ratio for any CV event was 0. 87 (95% CI, 0. 56 to 1. 34) for 3 to 6 MET hours/week-1, 0. 45 (95% CI, 0. 26 to 0. 80) for 9 to 12 MET hours/week-1, and 0. 47 (95% CI, 0. 23 to 0. 95) for 15 to 21 MET hours/week-1. Adherence to national vigorous intensity exercise guidelines (ie, ≥ 9 MET hours/week-1) was associated with a 51% reduction in the risk of any CV event in comparison with not meeting the guidelines (P =. 002).Conclusion: Vigorous exercise was associated with a lower risk of CV events in a dose-dependent manner ndependent of CV risk profile and treatment in survivors of HL.
UR - http://www.scopus.com/inward/record.url?scp=84911932838&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84911932838&partnerID=8YFLogxK
U2 - 10.1200/JCO.2014.56.7511
DO - 10.1200/JCO.2014.56.7511
M3 - Article
C2 - 25311213
AN - SCOPUS:84911932838
VL - 32
SP - 3643
EP - 3650
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 32
ER -